Cleary Gottlieb represented GlaxoSmithKline plc and GlaxoSmithKline Capital plc (a subsidiary of GlaxoSmithKline plc) in the offering by GlaxoSmithKline Capital of $1 billion of 0.750% Notes due 2015, $2 billion of 1.500% Notes due 2017 and $2 billion of 2.850% Notes due 2022. The notes, issued under a shelf registration statement and wholly and unconditionally guaranteed by GlaxoSmithKline plc, have been listed on the New York Stock Exchange. The offering closed on May 9.
GlaxoSmithKline plc is a major global healthcare company engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.
